Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Muscle-invasive bladder cancer treatment has shifted away from radical cystectomy toward bladder-preserving multimodal strategies since 2010. A SEER database analysis of nearly 10,500 patients found trimodality therapy and partial cystectomy with chemotherapy on the rise. While radical cystectomy still offers the best survival, adding chemotherapy to any approach meaningfully improves outcomes.
The way doctors treat muscle-invasive bladder cancer (MIBC) has changed significantly over the past decade. A new study in the World Journal of Urology analyzed nearly 10,500 patients from the SEER database diagnosed with T2N0M0 MIBC between 2010 and 2022, finding a clear shift away from radical cystectomy (full bladder removal) toward multimodal, bladder-preserving strategies.
Trimodality therapy — combining surgery, chemotherapy, and radiation — and partial cystectomy with chemotherapy have both grown substantially in use. Radical cystectomy still leads in overall survival, but partial cystectomy plus chemotherapy showed no statistically significant survival difference compared to it, suggesting real promise for carefully selected patients.
By the Numbers:
Why it matters: As more patients seek to preserve their bladder, these real-world trends highlight the growing role of multimodal therapy — but also underscore that patient selection and treatment standardization are critical to ensuring oncologic safety.
